Literature DB >> 16530509

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Uchenna H Iloeje1, Hwai-I Yang, Jun Su, Chin-Lan Jen, San-Lin You, Chien-Jen Chen.   

Abstract

BACKGROUND & AIMS: Cirrhosis develops as a result of hepatic inflammation and subsequent fibrosis in chronic hepatitis B infection. We report on the relationship between hepatitis B viremia and progression to cirrhosis in chronic hepatitis B infection.
METHODS: This was a population-based prospective cohort study of 3582 untreated hepatitis B-infected patients established in Taiwan from 1991 to 1992. Serum samples were tested for HBV DNA on cohort entry serum samples and the diagnosis of cirrhosis was by ultrasound.
RESULTS: During a mean follow-up time of 11 years, the 3582 patients contributed 40,038 person-years of follow-up evaluation and 365 patients were newly diagnosed with cirrhosis. The cumulative incidence of cirrhosis increased with the HBV-DNA level and ranged from 4.5% to 36.2% for patients with a hepatitis B viral load of less than 300 copies/mL and 10(6) copies/mL or more, respectively (P < .001). In a Cox proportional hazards model adjusting for hepatitis B e-antigen status and serum alanine transaminase level among other variables, hepatitis B viral load was the strongest predictor of progression to cirrhosis relative risk [95% confidence interval] was 2.5 [1.6-3.8]; 5.6 [3.7-8.5]; and 6.5 [4.1-10.2] for HBV-DNA levels >/=10(4) - <10(5); >/=10(5) - <10(6); >/=10(6) copies/mL, respectively.
CONCLUSIONS: These data show that progression to cirrhosis in hepatitis B-infected persons is correlated strongly with the level of circulating virus. The risk for cirrhosis increases significantly with increasing HBV-DNA levels and is independent of hepatitis B e-antigen status and serum alanine transaminase level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530509     DOI: 10.1053/j.gastro.2005.11.016

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  362 in total

1.  Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.

Authors:  Morris Sherman; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

2.  Clinical update: hepatitis B.

Authors:  Tram T Tran
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

3.  Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

Authors:  Moon Seok Choi; Byung Chul Yoo
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

4.  Understanding the natural history of chronic HBV and HCV infections.

Authors:  David L Thomas; Adrian M Di Bisceglie; Harvey J Alter; Norah A Terrault
Journal:  J Fam Pract       Date:  2010-04       Impact factor: 0.493

5.  Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma.

Authors:  Chia-Ming Chu; Chen-Chun Lin; Shi-Ming Lin; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2011-08-12       Impact factor: 3.199

6.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

Review 7.  Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.

Authors:  María Buti; Itziar Oyagüez; Virginia Lozano; Miguel A Casado
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

8.  Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?

Authors:  Kali Zhou; Norah Terrault
Journal:  AME Med J       Date:  2018-02-10

9.  Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.

Authors:  Hana Park; Jun Yong Park; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

10.  Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma.

Authors:  Myron J Tong; Lawrence M Blatt; Jia-Horng Kao; Jason Tzuying Cheng; William G Corey
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.